Mico BioMed Co. Ltd. (214610) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has a cash flow conversion efficiency ratio of -0.315x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.13 Billion ≈ $-5.51 Million USD) by net assets (₩25.81 Billion ≈ $17.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Mico BioMed Co. Ltd. worth for the company's overall valuation and market capitalisation.
Mico BioMed Co. Ltd. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mico BioMed Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their cash flow conversion efficiency. Explore 214610 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
-0.581x |
|
Orissa Bengal Carrier Limited
NSE:OBCL
|
0.015x |
|
Wegmans Holdings Berhad
KLSE:0197
|
-0.017x |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
0.024x |
|
Forgame Holdings Limited
F:FH0
|
0.001x |
|
Tomypak Holdings Bhd
KLSE:7285
|
-0.001x |
|
Embelton Ltd
AU:EMB
|
0.033x |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Mico BioMed Co. Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024. View Mico BioMed Co. Ltd. (214610) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩25.89 Billion ≈ $17.54 Million |
₩-10.70 Billion ≈ $-7.25 Million |
-0.413x | -32.16% |
| 2023-12-31 | ₩36.33 Billion ≈ $24.62 Million |
₩-11.36 Billion ≈ $-7.70 Million |
-0.313x | +60.50% |
| 2022-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-14.01 Billion ≈ $-9.49 Million |
-0.792x | -381.03% |
| 2021-12-31 | ₩52.26 Billion ≈ $35.42 Million |
₩-8.60 Billion ≈ $-5.83 Million |
-0.165x | +50.70% |
| 2020-12-31 | ₩55.96 Billion ≈ $37.92 Million |
₩-18.68 Billion ≈ $-12.66 Million |
-0.334x | +96.73% |
| 2019-12-31 | ₩1.02 Billion ≈ $691.72K |
₩-10.43 Billion ≈ $-7.07 Million |
-10.223x | -759.39% |
| 2018-12-31 | ₩5.71 Billion ≈ $3.87 Million |
₩-6.79 Billion ≈ $-4.60 Million |
-1.190x | -40.61% |
| 2017-12-31 | ₩3.42 Billion ≈ $2.32 Million |
₩-2.89 Billion ≈ $-1.96 Million |
-0.846x | +18.99% |
| 2016-12-31 | ₩3.83 Billion ≈ $2.59 Million |
₩-3.99 Billion ≈ $-2.71 Million |
-1.044x | -- |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more